Parotid-sparing IMRT for Nasopharyngeal Cancer
Completed
- Conditions
- Nasopharyngeal CancersIntensity Modulated Radiotherapy With Chemotherapy
- Interventions
- Radiation: Intensity modulated radiotherapy with chemotherapy
- Registration Number
- NCT02149641
- Lead Sponsor
- Royal Marsden NHS Foundation Trust
- Brief Summary
In the treatment of nasopharyngeal cancers, to determine the incidence of high grade (≥G2) subjective xerostomia at 1 year.
- Detailed Description
The purpose of this study was to determine the feasibility in delivering induction chemotherapy and concomitant chemotherapy with IMRT in the treatment of locally advanced nasopharyngeal cancers and to determine the incidence of high grade (≥G2) subjective xerostomia at 1 year.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 42
Inclusion Criteria
- nasopharyngeal cancers
Exclusion Criteria
- Patients <16 years old or with a previous malignancy other than non-melanomatous skin cancer were excluded
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Nasopharyngeal cancers Intensity modulated radiotherapy with chemotherapy Intensitiy modulated radiotherapy with chemotherapy
- Primary Outcome Measures
Name Time Method the incidence of ≥G2 xerostomia at 1 year using the subjective component LENTSOMA 12 months
- Secondary Outcome Measures
Name Time Method loco-regional disease-free survival (LRDFS), progression-free survival (PFS) and overall survival (OS) 2 years chemotherapy compliance and toxicities 0-12 weeks Acute radiation toxicities 0-3 months Late radiation toxicities 3-24 months
Trial Locations
- Locations (1)
The Royal Marsden NHS Foundation Trust
🇬🇧London, United Kingdom